Preparation and characterization of PEGylated amylin

AAPS PharmSciTech

Volumn 14, Issue 3, 2013, Pages 1083-1097

  Guerreiro, Luiz Henrique ^a   Guterres, Mariana F A N ^a   Melo Ferreira, Bruno ^a   Erthal, Luiza C S ^a   Da Silva Rosa, Marcela ^b   Lourenço, Daniela ^b   Tinoco, Priscilla ^a   Lima, Luís Maurício T R ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

amylin; diabetes; islet associated polypeptide; PEGylation; receptor activity modifying protein

Indexed keywords

AMINE; AMINO ACID; AMYLIN; DIMETHYL SULFOXIDE; FLUORESCAMINE; GLUCOSE; LYSINE; MACROGOL DERIVATIVE; METHOXY POLYETHYLENE GLYCOL SUCCINIMIDYL CARBONATE; METHOXY POLYETHYLENE GLYCOL SUCCINIMIDYL PROPIONATE; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; KINETICS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; ISLET AMYLOID POLYPEPTIDE; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYETHYLENE GLYCOLS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRYPSIN;

EID: 84890218967     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9987-4     Document Type: Article

References (74)

1. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 1991;34(1):52-4.
2. Young A. Amylin: physiology and pharmacology. 1st ed. San Diego: Elsevier Academic; 2005.
3. Cooper GJS. Amylin and related proteins: physiology and pathophysiology. In: Jefferson LS, Cherring AD, editors. Handbook of physiology. New York: Oxford University Press; 2001.
4. Cooper GJ. Amylin and insulin co-replacement therapy for insulin-dependent (type I) diabetes mellitus. Med Hypotheses. 1991;36(3):284-8.
5. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84(23):8628-32.
6. Cooper GJ, Willis AC, Reid KB, Clark A, Baker CA, Turner RC, et al. Diabetes-associated peptide. Lancet. 1987;2(8565):966.
7. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol. 1987;127(3):414-7.
8. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA. 1987;84(11):3881-5.
9. Cooper GJ, Leighton B, Dimitriadis GD, Parry-Billings M, Kowalchuk JM, Howland K, et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA. 1988;85(20):7763-6.
10. Young AA, Vine W, Gedulin BR, Pittner R, Janes S, Gaeta LS, et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Development Research. 1996;37:231-48.
11. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA. 1990;87(13):5036-40.
12. Guerreiro LH, Da SD, Ricci-Junior E, Girard-Dias W, Mascarenhas CM, Sola-Penna M, et al. Polymeric particles for the controlled release of human amylin. Colloids Surf B Biointerfaces. 2012;94:101-6.
13. Abuchowski A, Van ET, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977;252(11):3578-81.
14. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214-21.
15. Larson N, Ghandehari H. Polymeric conjugates for drug delivery. Chem Mater. 2012;24(5):840-53.
16. Youn YS, Na DH, Lee KC. High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation. J Control Release. 2007;117(3):371-9.
17. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-8.
18. Fee CJ. Protein conjugates purification and characterization. In: Veronese FM, editor. PEGylated protein drugs: basic science and clinical applications. 1st ed. Basel: Birkhäuser; 2009. p. 113-25.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(259):680-5.
20. Freitas DS, Abrahao NJ. Biochemical and biophysical characterization of lysozyme modified by PEGylation. International Journal of Pharmaceutics. 2010;392:111-7.
21. Scaramuzza S, Tonon G, Olianas A, Messana I, Schrepfer R, Orsini G, et al. A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: production and physicochemical characterization. J Control Release. 2012;164(3):355-63.
22. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nature Methods. 2012;9:671-5.
23. Wojdyr M. Fityk: a general-purpose peak fitting program. Journal of Applied Crystallography. 2010;43:1126-8.
24. Udenfriend S, Stein S, Bohlen P, Dairman W, Leimgruber W, Weigele M. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science. 1972;178(63):871-2.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem. 1976;72:248-54.
26. Strohalm M, Hassman M, Kosata B, Kodicek M. mMass data miner: an open source alternative for mass spectrometric data analysis. Rapid Communications in Mass Spectrometry. 2008;22(6):905-8.
27. Kusano S, Kukimoto-Niino M, Hino N, Ohsawa N, Okuda K, Sakamoto K, et al. Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding. Protein Sci. 2012;21(2):199-210.
28. Matozo HC, Santos MAM, Neto MD, Bleicher L, Lima LMTR, Iuliano R, et al. Low-resolution structure and fluorescence anisotropy analysis of protein tyrosine phosphatase eta catalytic domain. Biophys J. 2007;92(12):4424-32.
29. Panagiotidis G, Salehi AA, Westermark P, Lundquist I. Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse. Diabetes Res Clin Pract. 1992;18(3):167-71.
30. Guerreiro L, Da Silva D, Mizurini DM, Sola-Penna M, Lima LMTR. Amylin induces hypoglycemia in mice. An Acad Bras Cienc. 2013;85(1):143-8.
31. Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GI, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010;3(9-10):525-34.
32. Miller BT, Rogers ME, Smith JS, Kurosky A. Identification and characterization of O-biotinylated hydroxy amino acid residues in peptides. Analyt Biochem. 1994;219(2):240-8.
33. Miller BT, Kurosky A. Elevated intrinsic reactivity of seryl hydroxyl groups within the linear peptide triads His-Xaa-Ser or Ser-Xaa-His. Biochem Biophys Res Commun. 1993;196(1):461-7.
34. Banks PR, Paquette DM. Comparison of three common amine reactive fluorescent probes used for conjugation to biomolecules by capillary zone electrophoresis. Bioconjug Chem. 1995;6(4):447-58.
35. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002;54(4):459-76.
36. Gilead S, Wolfenson H, Gazit E. Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin. Angew Chem Int Ed Engl. 2006;45(39):6476-80.
37. Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006;443(7113):870-4.
38. Leuthauser K, Gujer R, Aldecoa A, McKinney RA, Muff R, Fischer JA, et al. Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition. Biochem J. 2000;351(Pt 2):347-51.
39. Tilakaratne N, Christopoulos G, Zumpe ET, Foord SM, Sexton PM. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther. 2000;294(1):61-72.
40. Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol. 2005;67(5):1655-65.
41. Sexton PM, Morfis M, Tilakaratne N, Hay DL, Udawela M, Christopoulos G, et al. Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. Ann N Y Acad Sci. 2006;1070:90-104.
42. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol. 1999;56(1):235-42.
43. Lakowicz JR. Principles of fluorescence spectroscopy. 2nd ed. New York: Plenum; 1999.
44. Eisenstein M. More than insulin. Nat Biotechnol. 2011;29(9):782-5.
45. Eliaschewitz FG, Aita CA, Genzini T, Noronha IL, Lojudice FH, Labriola L, et al. First Brazilian pancreatic islet transplantation in a patient with type 1 diabetes mellitus. Transplant Proc. 2004;36(4):1117-8.
46. Thorel F, Nepote V, Avril I, Kohno K, Desgraz R, Chera S, et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature. 2010;464(7292):1149-54.
47. Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1475-84.
48. Young DA, Deems RO, Deacon RW, McIntosh RH, Foley JE. Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol. 1990;259(3 Pt 1):E457-61.
49. Wei L, Jiang P, Yau YH, Summer H, Shochat SG, Mu Y, et al. Residual structure in islet amyloid polypeptide mediates its interactions with soluble insulin. Biochemistry. 2009;48(11):2368-76.
50. Jiang P, Wei L, Pervushin K, Mu Y. pH-Dependent interactions of human islet amyloid polypeptide segments with insulin studied by replica exchange molecular dynamics simulations. J Phys Chem B. 2010;114(31):10176-83.
51. Pharmaceuticals A. NDA 21-332 - Division of Pharmaceutical Evaluation-II. Office of Clinical Pharmacology and Biopharmaceutics. Symlin. Silver Spring: Food and Drug Administration; 2000.
52. Hashimoto M, Takada K, Kiso Y, Muranishi S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm Res. 1989;6(2):171-6.
53. Markussen J, inventor. Novo Industri A/S, assignee. Process for preparing esters of human insulin. Denmark patent US4343898; 1982.
54. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia. 1996;39(3):281-8.
55. Thibaudeau K, Leger R, Huang XC, Robitaille M, Quraishi O, Soucy C, et al. Synthesis and evaluation of insulin-human serum albumin conjugates. Bioconjugate Chemistry. 2005;16(4):1000-8.
56. Shechter Y, Mironchik M, Rubinraut S, Tsubery H, Sasson K, Marcus Y, et al. Reversible pegylation of insulin facilitates its prolonged action in vivo. European Journal of Pharmaceutics and Biopharmaceutics. 2008;70(1):19-28.
57. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nature Reviews Drug Discovery. 2010;9:267-8.
58. Hompesch M, Troupin B, Heise T, Elbroend B, Endahl L, Haahr H, et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab. 2006;8(5):568-73.
59. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 2000;39(35):10634-40.
60. Abedini A, Singh G, Raleigh DP. Recovery and purification of highly aggregation-prone disulfide-containing peptides: application to islet amyloid polypeptide. Analyt Biochem. 2006;351(2):181-6.
61. Milton NG, Harris JR. Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide. Micron. 2013;44:246-53.
62. Nilsson MR, Raleigh DP. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. J Mol Biol. 1999;294(5):1375-85.
63. Nilsson MR, Nguyen LL, Raleigh DP. Synthesis and purification of amyloidogenic peptides. Analyt Biochem. 2001;288(1):76-82.
64. Young A. Clinical studies. Adv Pharmacol. 2005;52:289-320.
65. Patil SM, Xu S, Sheftic SR, Alexandrescu AT. Dynamic alpha-helix structure of micelle-bound human amylin. J Biol Chem. 2009;284(18):11982-91.
66. Nanga RP, Brender JR, Xu J, Hartman K, Subramanian V, Ramamoorthy A. Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy. J Am Chem Soc. 2009;131(23):8252-61.
67. Singh G, Brovchenko I, Oleinikova A, Winter R. Peptide aggregation in finite systems. Biophys J. 2008;95(7):3208-21.
68. Larson JL, Miranker AD. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J Mol Biol. 2004;335(1):221-31.
69. Knight JD, Williamson JA, Miranker AD. Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin. Protein Sci. 2008;17(10):1850-6.
70. Wiltzius JJ, Sievers SA, Sawaya MR, Eisenberg D. Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process. Protein Sci. 2009;18(7):1521-30.
71. Yonemoto IT, Kroon GJ, Dyson HJ, Balch WE, Kelly JW. Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. Biochemistry. 2008;47(37):9900-10.
72. Cabaleiro-Lago C, Lynch I, Dawson KA, Linse S. Inhibition of IAPP and IAPP(20-29) fibrillation by polymeric nanoparticles. Langmuir. 2010;26(5):3453-61.
73. Rijkers DT, Hoppener JW, Posthuma G, Lips CJ, Liskamp RM. Inhibition of amyloid fibril formation of human amylin by N-alkylated amino acid and alpha-hydroxy acid residue containing peptides. Chemistry. 2002;8(18):4285-91.
74. Mazzaglia A, Micali N, Scolaro LM, Attanasio F, Magri A, Pappalardo G, et al. Aggregation properties of the peptide fragments derived from the 17-29 region of the human and rat IAPP: a comparative study with two PEG-conjugated variants of the human sequence. J Phys Chem B. 2010;114(2):705-13.